Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_131_библиотеки_им_акад_М_И_Перельмана
.pdf
121
215. Opal, S.M. Clinical gram-positive sepsis: does it fundamentally differ from
gram-negative bacterial sepsis? / S.Opal [et al.]. // Crit. Care Med. –1999. –
V. 2 7. – Ɋ. 1608–1616.
216. Otto, G.P. The late phase of sepsis is characterized by an increased
microbiological burden and death rate / G.P. Otto [et al.]. // Critical care. –
2011. – V. 15(4). – P. 183.
217. Pachot, A. Longitudinal study of cytokine and immune transcription factor
mRNA expression in septic shock / A. Pachot // Clin Immunol. – 2005. –
V. 114(1). – Ɋ. 61–69.
218. Paganini, A.M. Follow-up of 161 unselected consecutive patients treated
lapa-roscopically for common bile duct stones / A.M. Paganini [et al.]. // Surg
Endosc 1998. – V. 12. – P. 23–29.
219. Paine, R. A randomized trial of recombinant human granulocyte-macrophage
colony stimulating factor for patients with acute lung injury / R. Paine // Crit
Care Med. – 2012. – V. 40(1). – Ɋ. 90–97.
220. Palsson-McDermott,
E.M.
Signal
transduction
by
the
lipopolysaccharide
receptor,
Toll-like
receptor-4
/
E.M. Palsson-
McDermott
//
Immunology.
–
2004.
–
V. 113, P. 153–162.
221. Pastille, E. Modulation of dendritic cell differentiation in the bone marrow
mediates sustained immunosuppression after polymicrobial sepsis / E. Pastille
// J Immunol. – 2011. – V. 186(2). – Ɋ. 977–986.
222. Patera, A.C. Frontline Science: Defects in immune function in patients with
sepsis are associated with PD-1 or PD-L1 expression and can be restored by
antibodies targeting PD-1 or PD-L1 / A.C. Patera [et al.]. // J Leukoc Biol. –
2016. – V. 100(6). – P. 1239–1254.
223. Pelletier, M. Mechanisms in Vved in interleukin-15-induced suppression of
human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and
several kinases including Janus kinase-2, p38 mitogen-activated protein kinase
and extracellular signal-regulated kinases-1/2 / M. Pelletier // FEBS Lett. –
2002. – V. 532(1–2). – Ɋ. 164–170.
224. Perales, M.A. Recombinant human interleukin-7 (CYT107) promotes T-cell
recovery after allogeneic stem cell transplantation / M.A. Perales [et al.]. //
Blood. – 2012. – V. 120(24). – Ɋ. 4882–4891.
225. Peter, K. Experiences and Conclusions of the Hungarian Emergency Sepsis
Register / K. Peter [et al.]. // Open Journal of Epidemiology. – 2017. – V. 7. –
P. 44–58.
226. Peters van Ton, A.M. Precision Immunotherapy for Sepsis / A.M. Peters van
Ton [et al] // Front. Immunol. – 2016. – T. 9. – P. 19–26.
227. Pilz, G. Comparison of early IgM-enriched immunoglobulin vs polyvalent
IgG administration in score-identified postcardiac surgical patients at high risk
for sepsis / G. Pilz // Chest. – 1997 Feb. – V. 111(2). – Ɋ. 419–426.
https://t.me/med1917
122
228. Pilz, G. Evaluation of definitions of sepsis / G. Pilz [et al.] // Chest. – 1994. –
V. 105 (3). – P. 970–971.
229. Poli, A. CD56bright natural killer (NK) cells: an important NK cell subset /
A. Poli // Immunology. – 2009. – V. 126(4). – Ɋ. 458–465.
230. Prondzinsky, R. Systemische Entzündungsreaktionen extrakorporaler
Therapieverfahren (II): Der kardiopulmonale Bypass [Systemic inflammatory
reactions to extracorporeal therapy measures (II): Cardiopulmonary bypass] /
R. Prondzinsky [et al.] // Wien Klin Wochenschr. – 1997. – V. 109 (10). –
P. 346–353.
231. Prowle, J.R. Acquired bloodstream infection in the intensive care unit:
incidence and attributable mortality / J.R. Prowle [et al.]. // Critical care
(London, England). – 2011. – V. 15(2). – P. 100.
232. Rauch, P.J. Innate response activator B cells protect against microbial sepsis /
P.J. Rauch [et al.]. // Science. – 2012. – V. 335(6068). – Ɋ. 597–601.
233. Reith, H.B. IgMenriched immunoglobulin (pentaglobin) positively influences
the course of post-surgical intra-abdominal infections / H.B. Reith [et al.]. //
Eur. J. Med. Res. – 2004 Oct 29. – V. 9(10). – Ɋ. 479–84.
234. Ren-Wen Tsay, L. Characteristics of Bacteremia Between Community-
Acquired and Nosocomial Klebsiella pneumoniae Infection: Risk Factor for
Mortality and the Impact of Capsular Serotypes as a Herald for Community-
Acquired Infection / L. Ren-Wen Tsay [et al.]. // Arch. Intern. Med. – 2002. –
V. 162 (9). – P. 1021–1027.
235. Repp, R. Neutrophils express the high affinity receptor for IgG (Fc gamma
RI, CD64) after in vivo application of recombinant human granulocyte
colonystimulating factor / R. Repp [et al.]. // Blood. – 1991. – V. 78(4). –
Ɋ. 885–8899.
236. Retsas T. Haplotypes composed of minor frequency single nucleotide
polymorphisms of the TNF gene protect from progression into sepsis: A study
using the new sepsis classification / T. Retsas [et al.]. // International Journal of
Infectious Diseases. – 2018. – V. 67. – Ɋ. 102-106.
237. Rhodes, A. Surviving Sepsis Campaign: International Guidelines for
Management of Sepsis and Septic Shock: 2016 / A. Rhodes // Intensive
CareMed. – 2017 Mar. – V. 43(3). – Ɋ. 304–377.
238. Rice, L. Federal Funding for the study of antimicrobial resistance in
nosocomial pathogens: No ESKAPE / L. Rice // J. Infect. Dis. – 2008. –
V. 197. – P. 1079–1081.
239. Rietschel,
E.T.
Endotoxin:
historical
perspectives.
In:
Endotoxin
in health
and
disease
/
E.T. Rietschel
//
New
Yo rk ,
1999.
–
Marcel
Dekker,
P. 1–30.
240. Rittirsch, D. Harmful molecular mechanisms in sepsis / D. Rittirsch // Nat
Rev Immunol. – 2008. – V. 8(10). – Ɋ. 776–787.
https://t.me/med1917
123
241. Rodríguez, A. Effects of high-dose of intravenous immunoglobulin and
antibiotics on survival for severe sepsis undergoing surgery / A. Rodríguez [et
al.] // Shock. – 2005. – V. 23 (1). – P. 298–304.
242. Rodríguez-Créixems, M. Bloodstream infections: e Vution and trends in the
microbiology workload, incidence, and etiology, 1985–2006 / M. Rodríguez-
Créixems [et al.] // Medicine. – 2008. – V. 87(4). – P. 234–249.
243. Salkowski,
C.A.
Pulmonary
and Hepatic
Gene
Expression
following
Cecal
Ligation
and
Puncture:
Monophosphoryl
Lipid
A
Prophylaxis
Attenuates
Sepsis-Induced
Cytokine
and Chemokine
Expression
and
Neutrophil
Infiltration
/
C.A. Salkowski
//
Infect.
Immun.
–
1998.
–
V. 66(8).
–
P. 3569–3578.
244. Salnikova, L.Ye. Geneticheskaja predraspolozhennost k razvitiju ostroj
vnebolnichnoj pnevmonii [Genetic Predisposition to the Development of Acute
Community-Acquired Pneumonia]. – Obshhaja reanimatologija [General
Reanimatology]. – 2010. – V. 6(1). – 5–10.
245. Sands, K.E. Epidemiology of sepsis syndrome in 8 academic medical centers
/ K.E. Sands [et al.] // JAMA: the journal of the American Medical Association.
– 1997. – V. 278(3). – P. 234–240.
246. Scumpia, P.O. Cutting edge: bacterial infection induces hematopoietic stem
and progenitor cell expansion in the absence of TLR signaling / P.O. Scumpia
// J Immunol. – 2010. – V. 184(5). – Ɋ. 2247–2251.
247. Sergeyev, S.A. Rol geneticheskogo polimorfizma v razvitii sepsisa u detej
[Role of genetic polymorphism in the development of sepsis in infants]. –
Patologija krovoobrashhenija i kardiohirurgija [Circulation Pathology and
Cardiac Surgery]. – 2013. – V. 17(4). – Ɋ. 59–62.
248. Seymour, C.W. Assessment of clinical criteria for sepsis. For the Third
International consensus definitions for sepsis and septic shock (Sepsis-3) / C.W.
Seymour [et al.] // JAMA. – 2016. – 315(8). – P. 762–774.
249. Shakoory, B. Interleukin-1 Receptor blockade is associated with reduced
mortality in sepsis patients with features of macrophage activation syndrome:
reanalysis of a prior phase III trial / B. Shakoory [et al.]. // Crit Care Med. –
2016. – V. 44. – P. 275–281.
250. Shankar-Hari, M. Developing a new definition and assessing new clinical
criteria for septic shock: for the Third International Consensus Definitions for
Sepsis and Septic Shock (Sepsis-3) / M. Shankar-Hari [et al.]. // JAMA. – 2016.
– V. 315(8). – Ɋ. 775–787.
251. Shao, Y. Association study between promoter polymorphismsof ADAM17
and progression of sepsis / Y. Shao // Cellular Physiology, Biochemistry. –
2016. – V. 39(4). – Ɋ. 1247–1261.
252. Shozushima, T. Usefulness of presepsin (sCD14-ST) measurements as a
marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria
https://t.me/med1917
124
of systemic inflammatory response syndrome / T. Shozushima [et al.]. //
J Infect Chemother. – 2011. – V. 17(6). – Ɋ. 764–769.
253. Singer, M. The Third International Consensus Definitions for Sepsis and
Septic Shock (Sepsis-3) / M. Singer [et al.]. // JAMA. – 2016. – V. 315(8). –
Ɋ. 801–810.
254. Sironi, M. E Vutionary insights into host-pathogen interactions from
mammalian sequence data / M. Sironi [et al.]. // Nat Rev Genet. – 2015. –
V. 16(4). – Ɋ. 224–236.
255. Siuger, D. Post-spenectomy sepsis in pediatric pathology / D. Siuger //
Chicago: Year Book Med. – 1976. – P. 235–311.
256. Smeekens, S.P. Functional genomics identifies type I interferon pathway as
central for host defense against Candida albicans / S.P. Smeekens // Nat
Commun. – 2013. – 4.
257. Soni, N.J. Procalcitonin-Guided Antibiotic Therapy: A Systematic Review
and Meta-analysis / N.J. Soni [et al.]. // Journal of Hospital Medicine. – 2013. –
V. 8 (9 ) .
258. Sorensen, T.I. Genetic and environmental influences on premature death in
adult adoptees / T.I. Sorensen [et al.]. // New England Journal of Medicine. –
1988. – 318(12). – Ɋ. 727–732.
259. SouzaNeto J.L. Effects of simvastatin in abdominal sepsis in rats / J.L.
SouzaNeto [et al.]. // Acta Cir Bras. – 2006. – 21(Suppl 4). – Ɋ. 8–12.
260. Spanuth, E. Diagnostic and prognostic value of presepsin (soluble CD14
subtype) in emergency patients with early sepsis using the new assay
PATHFAST Presepsin [C]. 21st International Congress of Clinical Chemistry
and Laboratory Medicine, IFCC – World Lab – Euro Med Lab, Berlin, 2011.
261. Spellberg, B. Mistaken or Maligned? / B. Spellberg [et al.]. // Clinical
Infectious Diseases. – 2008. – V. 47. – P. 294.
262. Sucher, J.F. Computerized clinical decision support: a technology to
implement and validate evidence based guidelines / J.F. Sucher [et al.]. //
J Trauma Inj Infect Critic Care. – 2008. – V. 64. – Ɋ. 520–37.
263. Tabah, A. Characteristics and determinants of outcome of hospital-acquired
bloodstream infections in intensive care units: the EUROBACT International
Cohort Study / A. Tabah [et al.]. // Intensive care medicine. – 2012. –
V. 38(12). – P. 1930–1945.
264. Teuffel, O. Association between tumor necrosis factor-alpha promoter-308
A/G polymorphism and susceptibility to sepsis and sepsis mortality: a
systematic review and meta-analysis / O. Teuffel // Critical Care Medicine. –
2010. – V. 38(1). – Ɋ. 276–282.
265. The 28th ESICEM. EPIC II study investigator meeting (oral presentation,
unpublished). – Brussels, March 2008.
https://t.me/med1917
125
266. Thomsen, R.W. Statin use and mortality within 180 days after bacteremia: a
population-based cohort study / R.W. Thomsen // Crit Care Med. – 2006. –
V. 34. – Ɋ. 1080–1086.
267. Tian, H.C. Epidemiology of Sepsis-3 in a sub-district of Beijing: secondary
analysis of a population-based database / H.C. Tian [et al.] // Chin Med J. –
2019. – V. 132. – Ɋ. 2039–2045.
268. Tidswell,
M.
Phase
2
trial
of
eritoran
tetrasodium
(E5564),
a
toll-like
receptor
antagonist,
in
patients
with
severe
sepsis
/
M. Tidswell
//
Crit.
Care.
Med.
–
2010.
– V. 38. – P. 72–83.
269. Toliver-Kinsky, T.E. Stimulation of hematopoiesis by the Fms-like tyrosine
kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally
injured mice / T.E. Toliver-Kinsky // Infect Immun. – 2003. – V. 71(6). –
Ɋ. 3058–3067.
270. Unsinger, J. IL-7 promotes T-cell viability, trafficking, and functionality and
improves survival in sepsis / J. Unsinger [et al.] // J Immunol. – 2010. – V. 184.
– P. 3768–3779.
271. Uraski, U. Splenektomia w swiete wspoezecnych pogladow / U. Uraski //
Polski tigodnik lekarski. – 1982. – V. 37. – P. 1109–1112.
272. van
Amersfoort,
E.S.
Receptors,
mediators,
and mechanisms
in Vved
in
bacterial
sepsis
and
septic
shock
/
E.S. van
Amersfoort
//
Clin.
Microbial.
Rev. – 2003.
–
V. 16(3).
–
P. 379–414.
273. Venet, F. Regulatory T cell populations in sepsis and trauma / F. Venet //
J Leukoc Biol. – 2008. – V. 83(3). – Ɋ. 523–535.
274. Vincent, J.L. qSOFA does not replace SIRS in the definition of sepsis / J.L.
Vincent [et al.]. // Critical. Care. – 2016. – V. 20. – Ɋ. 210.
275. Vodnik, T. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal
sepsis / Vodnik T. [et al.]. // Clin Chem Lab Med. – 2013. – V. 51(10). –
Ɋ. 2053–2062.
276. Veti, B. Statins and nitric oxide reduce C-reactive protein production while
inÀammatory conditions persist / B. Veti [et al.]. // Mol Immunol. – 2006. –
V. 43. – Ɋ. 891–896.
277. Wacharasint, P. Single nucleotide polymorphisms of IL-10 family members
are associated with increased mortality in septic shock / P. Wacharasint [et al.].
// In: 35
th
Annual Conference on Shock; At Miami Beach, Florida. – 2012. –
P. 55. (Shock; no. 37, suppl. 1).
278. Wang, H. The association of polymorphisms of TLR4 and CD14 genes with
susceptibility to sepsis in a Chinese populyation / H. Wang [et al.]. // BMC
Medical Genetics. – 2014. – V. 15. – 123.
279. Wang, J.F. Up-regulation of programmed cell death 1 ligand 1 on neutrophils
may be in Vved in sepsis-induced immunosuppression: an animal study and a
https://t.me/med1917
126
prospective case-control study / J.F. Wang // Anesthesiology. – 2015. –
V. 122(4). – Ɋ. 852–863.
280. Ward, P.A. Bosmann M. A historical perspective on sepsis / P.A. Ward // Am
J Pathol. – 2012. – V. 181(1). – Ɋ. 2–7.
281. Waterer, G.W. Science review: Genetic variability- in the systemic
inflammatory response / G.W. Waterer // Critical Care Medicine. – 2003. –
V. 7(4). – Ɋ. 308–314.
282. Weber, G.F. Interleukin-3 amplifies acute inflammation and is a potential
therapeutic target in sepsis / G.F. Weber // Science. – 2015. – V. 347(6227). –
Ɋ. 1260–1265.
283. Wilkinson, T.S. Ventilator-associated pneumonia is characterized by
excessive release of neutrophil proteases in the lung / // Chest. – 2012. –
V. 142(6). – Ɋ. 1425–1432.
284. Winters, B.D. Long-term mortality and quality of life in sepsis: a systematic
review / B.D. Winters [et al.]. // Critical care medicine. – 2010. – V. 38(5). –
P. 1276–1283.
285. Wisplinghoff, H. Current trends in the epidemiology of nosocomial
bloodstream infections in patients with hematological malignancies and solid
neoplasms in hospitals in the United States / H. Wisplinghoff [et al.]. // Clinical
infectious diseases: an official publication of the Infectious Diseases Society of
America. – 2003. – V. 36(9). – P. 1103–1110.
286. Wu, H.P. Associations of T helper 1, 2, 17 and regulatory T lymphocytes
with mortality in severe sepsis / H.P. Wu // Inflamm Res. – 2013. – V. 62(8). –
Ɋ. 751–763.
287. Xiao, W. A genomic storm in critically injured humans / W. Xiao // J Exp
Med. – 2011. – V. 208(13). – Ɋ. 2581–2590.
288. Xue, B. Human NRAGE disrupts E-cadherin/beta-catenin regulated
homotypic cell-cell adhesion / B. Xue // Biochemical and Biophysical Research
Communications. – 2005. – V. 336(1). – Ɋ. 247-251.
289. Yaegashi, Y. Evaluation of a newly identified soluble CD14 subtype as a
marker for sepsis / Y. Yaegashi // J Infect Chemother. – 2005. – V. 11(5). –
Ɋ. 234–238.
290. Yamada, T. IL18 production and IL18 promoter polymorphisms correlate
with mortality in ICU patients / T. Yamada // In Vivo. – 2014. – V. 28(3). –
Ɋ. 391–396.
291. Yende, S. Inflammatory markers at hospital discharge predict subsequent
mortality after pneumonia and sepsis / S. Yende // Am J Respir Crit Care Med.
– 2008. – V. 177(11). – Ɋ. 1242–1247.
292. Zanin-Zhorov, A. Heat shock protein 60 enhances CD4
+
CD25
+
regulatory
T cell function via innate TLR2 signaling / A. Zanin-Zhorov // J Clin Invest. –
2006. – V. 116(7). – Ɋ. 2022–2032.
https://t.me/med1917
293. Zhang, A-Q. Association between CD14 promoter-159C/T polymorphism
and the risk of sepsis and mortality: a systematic review and meta-analysis
/ A-Q. Zhang // PLoS One [Internet]. – 2013. – V. 8(8): e71237.
294. Zhang, Y. Upregulation of programmed death-1 on T cells and programmed
death ligand-1 on monocytes in septic shock patients / Y. Zhang [et al.]. // Crit
Care. – 2011. – V. 15. – P. 70.
295. Zheng, D. Inflammasome activation and regulation: toward a better
understanding of complex mechanisms / // Cell Discov. – 2020. – V. 6. –
Ɋ. 36.
296. Ziegler, U.E. Clinical correlation between the consumption of nicotine and
cotinine concentrations in urine and serum by competitive enzyme-linked
immunosorbent assay. Pharmacology / U.E. Ziegler [et al.] // 2004. – V. 72(4).
– P. 254–259.
297. Zweigner, J. The role of lipopolysaccharide-binding protein in modulating the
innate immune response / J. Zweigner [et al.]. // Microbes Infect. – 2006. –
V. 8(3). – Ɋ. 946–952.
https://t.me/med1917
Для
связи с авторами:
felache3@yandex.ru
Научное издание
Богдан Николаевич Котив,
Борис Юриевич Гумилевский,
Оксана Петровна Гумилевская,
Феликс Викторович Иванов
ИЗБРАННЫЕ ВОПРОСЫ ДИАГНОСТИКИ
И ЛЕЧЕНИЯ БАКТЕРИАЛЬНОГО СЕПСИСА
Монография
Дизайн обложки Т. Б. Тиунова
Подписано в печать 30.03.2022. Формат 60 × 90
1
/
16
.
Усл. печ. л. 8,0. Печать цифровая.
Заказ № 076С.
Отпечатано с готового оригинал-макета в типографии
издательско-полиграфической фирмы «Реноме»,
192007, Санкт-Петербург, наб. Обводного канала, д. 40. Тел.
(812) 766-05-66.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана